On August 20, the results of the third batch of centralized drug procurement organized by the state were publicized, with an average decrease of 53% and a maximum drop of 95%. The price was as low as 1.5 cents per tablet. This centralized procurement involves 55 kinds of drugs, such as malignant tumor, hypertension, diabetes, and psychiatric diseases, and the number of varieties is close to the sum of the first two batches. < p > < p > as of the press release, 13 A-share listed companies have announced their intention to win the bid for centralized procurement with quantity. Listed companies generally believe that drug selection is conducive to enhancing product competitiveness, increasing market share, and having a positive impact on the company’s future business performance. A person in charge of a pharmaceutical enterprise in Beijing told the reporter of securities times · e company that centralized drug procurement will become a normal policy and the market pattern of the pharmaceutical industry will also be reshaped. “Centralized purchasing has changed the original sales mode in the industry and avoided the rent-seeking space in the circulation link. On the other hand, as the entry threshold, consistency evaluation encourages pharmaceutical enterprises to carry out R & D and innovation. In the long run, purchasing with volume will play a positive role in the healthy development of the industry. ” < / P > < p > after the announcement of the bid winning results of centralized drug procurement in the alliance area, many pharmaceutical listed companies sent “good news”, including 6 varieties of Shanghai medicine and 5 varieties of Fuxing medicine. < p > < p > on August 20, Shanghai Pharmaceutical (601607) announced that the company and its subsidiaries participated in the bidding work of the third batch of national centralized drug procurement organized by the joint procurement organization. The imitated drugs metformin hydrochloride tablets (0.25g), Ambroxol Hydrochloride Capsules (30mg), ibuprofen sustained-release capsules (0.3g), dexzopiclone tablets (3mg), fluoxetine hydrochloride capsules (20mg) and captopril tablets (12.5mg, 25mg) were purchased intensively, and the company selected provinces according to the market potential of each province. < p > < p > Fosun Pharmaceutical (600196) announced that five drugs, including febuxostat tablets, quetiapine fumarate tablets, pivastatin calcium tablets, ethambutol hydrochloride tablets and memantine hydrochloride tablets, are to be selected for the third batch of centralized procurement of national drugs. If the subsequent signing and implementation of the procurement contract, will be conducive to further expand the sales scale of related products, improve market share. < / P > < p > Modern Pharmaceutical (600420) also said that clarithromycin tablets (0.25g) and cefdinir dispersible tablets (0.1g) were selected for this centralized purchase. HongRi Pharmaceutical (300026) moxifloxacin hydrochloride and sodium chloride injection (trade name: enrotai) participated in the centralized procurement and won the bid. < / P > < p > e’s reporter learned that Domperidone Tablets (vinorelbine) of Yiming medicine (002826) was successfully awarded the bid in this national centralized purchase. Viagra, a wholly-owned subsidiary of the company, started the conformity evaluation of Domperidone Tablets in June 2016; on September 6, 2019, Viagra’s Domperidone Tablets passed the consistency evaluation. Two varieties of Huadong medicine (000963) (anastrozole tablets (1mg) and Domperidone Tablets (10mg)) were successfully won the bid. In addition, Haizheng Pharmaceutical (600267), Jianmin group (600976), Baiyunshan (600332), Chengxin Pharmaceutical (603811), Jiuzhoutong (600998) and wanbangde (002082) are also listed in the third batch of national centralized drug procurement. < / P > < p > the competition of this centralized purchase is no less than that of the previous two. According to statistics, a total of 189 enterprises participated in the procurement, including 125 enterprises to be selected, 191 products to be selected, and 55 varieties of drugs to win the bid. The average price reduction of the products to be won the bid was 53%, and the highest drop rate was as high as 95%. < / P > < p > from the perspective of bid winning price, there are drugs with the highest price reduction of more than 90% in the first two batches of centralized purchase, and the price reduction range is closely related to the degree of competition. The third batch of metformin, a diabetes drug with the largest reported volume, reached 4.66 billion tablets, accounting for more than 20% of the total reported volume. This is the most competitive variety. A total of 44 enterprises participated in the quotation, and only 15 enterprises were expected to win the bid. The highest bid price was only 0.12 yuan / tablet. The bid price of 0.5g * 10 tablets / box of Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd. was only 0.78 yuan, less than 10 cents on average. < / P > < p > it is worth noting that there are several drugs with sub pricing in the bid winning list of centralized purchase. In addition to metformin, the bid price of captopril tablets is as low as 2 cents. Chongqing Kerui Pharmaceutical (Group) Co., Ltd. won the bid for a box of 84 tablets (25mg / tablet) of captopril tablets. The bid price of each tablet was only 1.19 yuan, and the price of each tablet was only 1.4 cents. The highest bid price of other enterprises was only 3 cents / tablet. Sildenafil citrate tablets (Viagra), a domestic aphrodisiac, which was once considered to have a low price reduction intention, also made a substantial price reduction in this round of collection. Finally, Qilu pharmaceutical was the only company to win the bid. The bid price of each box of 25mg * 12 tablets was 24.98 yuan, with an average of about 2 yuan per tablet, a decrease of more than 90%. < / P > < p > the scale of centralized drug procurement is large. According to the data of MI Nei net, the total sales of these 56 varieties in China’s public medical institutions will exceed 54 billion yuan in 2019. According to the first year’s agreed purchase quantity and the highest effective quotation, the maximum agreed purchase amount involved in the third batch of centralized purchase is about 22.64 billion yuan. With the rapid increase of purchasing quantity, the policy of centralized purchase has been normalized. With the implementation of the normalized policy, investors have no longer changed their color, and the short-term stock price reaction degree of related enterprises is no longer as large-scale drop limit as in the “4 + 7” pilot project. On the morning of August 20, the third batch of enterprises planning to win the bid for centralized procurement came out, and the Shenwan pharmaceutical and biological industry index fell slightly by 0.62% throughout the day, and it also turned red in the afternoon, and relevant enterprises went out of the differentiation market. Shanghai pharmaceutical, which plans to win six products, fell by 2.07%, while Fosun Pharmaceutical, which plans to win five products, rose by 1.18%. Dongguan securities analysts said that generally speaking, the third batch of centralized purchasing has less negative impact on the domestic enterprises that have been appraised, while the “barefoot” varieties can get the opportunity to trade in the price and occupy a place in the market, and pay attention to the reconstruction of the competition pattern of related varieties. From the perspective of policy trends, centralized purchasing will be normalized in the future. It is estimated that in the next three years, the national centralized purchase plan will be carried out for another three years, and 5-6 batches will be made. The goal is to focus on the top 160 varieties of hospital procurement from high to low. < / P > < p > in addition, the analyst also believes that in the future, the varieties not involved in the national procurement may be included in the provincial and municipal centralized purchase, the number of covered varieties will also increase, and the categories covered will be extended to biological agents, Chinese patent medicines, etc. In the medium and long term, they focus on the head innovative pharmaceutical enterprises with rich product lines and strong R & D strength. < / P > < p > under the normalization of centralized purchase, the coping strategies of retail pharmaceutical enterprises are also one of the focuses discussed in Boao west general meeting in Hainan this year. The board directors of Yifeng pharmacy and common people pharmacy think that the impact can be almost negligible. Gao Yi, chairman of Yifeng pharmacy, believes that the impact of centralized purchasing should be divided into early, medium and late stages. The early impact is not big. In the medium term, with the wider range of purchasing with volume, the gross profit rate of the whole industry will be lowered. There will be a small cold in the last spring before the arrival of large-scale outflow of hospital prescriptions, but it will promote the integration of the industry. Xie Zilong, chairman of the people’s pharmacy, thinks that the impact of Jicai on retail pharmacies can be ignored or negligible. After “4 + 7”, in addition to the successful enterprises will actively communicate with retail pharmacies to pay part of the distribution costs, the unsuccessful varieties are also “forced” to cooperate with retail stores because they are “driven out” by the medical insurance bureau.